Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fulcrum Therapeutics (FULC) Share-based Compensation: 2019-2025

Historic Share-based Compensation for Fulcrum Therapeutics (FULC) over the last 7 years, with Sep 2025 value amounting to $3.4 million.

  • Fulcrum Therapeutics' Share-based Compensation fell 11.97% to $3.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.9 million, marking a year-over-year decrease of 23.49%. This contributed to the annual value of $14.6 million for FY2024, which is 1.68% down from last year.
  • As of Q3 2025, Fulcrum Therapeutics' Share-based Compensation stood at $3.4 million, which was up 16.87% from $2.9 million recorded in Q2 2025.
  • In the past 5 years, Fulcrum Therapeutics' Share-based Compensation ranged from a high of $4.3 million in Q2 2024 and a low of $2.1 million during Q1 2021.
  • Over the past 3 years, Fulcrum Therapeutics' median Share-based Compensation value was $3.4 million (recorded in 2023), while the average stood at $3.5 million.
  • As far as peak fluctuations go, Fulcrum Therapeutics' Share-based Compensation skyrocketed by 126.18% in 2021, and later plummeted by 33.82% in 2025.
  • Fulcrum Therapeutics' Share-based Compensation (Quarterly) stood at $3.8 million in 2021, then decreased by 13.76% to $3.3 million in 2022, then rose by 5.44% to $3.4 million in 2023, then fell by 28.18% to $2.5 million in 2024, then declined by 11.97% to $3.4 million in 2025.
  • Its Share-based Compensation stands at $3.4 million for Q3 2025, versus $2.9 million for Q2 2025 and $3.2 million for Q1 2025.